Oluwatobi Omoworare
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Oluwatobi Omoworare has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Emmanuel Kokori
University of Ilorin, Ilorin, Nigeria
6 shared publications - Nicholas Aderinto
Ladoke Akintola University of Technology, Ogbomosho, Nigeria
6 shared publications - Adetola Emmanuel Babalola
Kornberg School of Dentistry, Temple University, Philadelphia, USA
3 shared publications - Gbolahan Olatunji
Department of Medicine and Surgery, University of Ilorin, Ilorin, Nigeria
3 shared publications - Ikponmwosa Jude Ogieuhi
Siberian State Medical University
3 shared publications - Israel Charles Abraham
University of Ilorin, Ilorin, Nigeria
3 shared publications
Latest Publications
- Open Access
- 6 March 2026
- Published by Springer Nature in The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
- Vol. 62 (1) , 65
The impact of kidney dysfunction on blood-brain barrier integrity and neurological conditions
The kidney–brain axis represents a bidirectional pathophysiological link between chronic kidney disease (CKD), acute kidney injury (AKI), and blood–brain barrier (BBB) dysfunction. CKD affects over 800 million individuals globally and is associated with accelerated cognitive decline, stroke, and neurodegenerative disorders. This review synthesizes evidence that uremic toxins, systemic inflammation, oxidative stress, hormonal dysregulation (erythropoietin deficiency, RAAS activation), and gut dysbiosis converge to impair BBB integrity via tight junction degradation, endothelial activation, and pericyte–astrocyte decoupling. These alterations facilitate neuroinflammation, neurotoxicity, and leukocyte infiltration, contributing to the pathogenesis of stroke, Alzheimer’s disease, Parkinson’s disease, epilepsy, and CKD-associated leukoencephalopathy. Hemodialysis-induced osmotic shifts and sleep fragmentation further exacerbate BBB and glymphatic dysfunction. Preserving BBB integrity through uremic toxin reduction, anti-inflammatory strategies, RAAS inhibition, and lifestyle interventions (e.g., exercise) emerges as a critical therapeutic goal. Future research must prioritize biomarker validation (claudin-5, S100B), neuroimaging correlations, and targeted BBB-protective therapies to mitigate neurological morbidity in renal disease.
- 6 March 2026
- Published by Springer Nature in The Egyptian Journal of Neurology, Psychiatry and Neurosurgery
- Vol. 62 (1) , 65
Open AccessThe impact of kidney dysfunction on blood-brain barrier integrity and neurological conditions
The kidney–brain axis represents a bidirectional pathophysiological link between chronic kidney disease (CKD), acute kidney injury (AKI), and blood–brain barrier (BBB) dysfunction. CKD affects over 800 million individuals globally and is associated with accelerated cognitive decline, stroke, and neurodegenerative disorders. This review synthesizes evidence that uremic toxins, systemic inflammation, oxidative stress, hormonal dysregulation (erythropoietin deficiency, RAAS activation), and gut dysbiosis converge to impair BBB integrity via tight junction degradation, endothelial activation, and pericyte–astrocyte decoupling. These alterations facilitate neuroinflammation, neurotoxicity, and leukocyte infiltration, contributing to the pathogenesis of stroke, Alzheimer’s disease, Parkinson’s disease, epilepsy, and CKD-associated leukoencephalopathy. Hemodialysis-induced osmotic shifts and sleep fragmentation further exacerbate BBB and glymphatic dysfunction. Preserving BBB integrity through uremic toxin reduction, anti-inflammatory strategies, RAAS inhibition, and lifestyle interventions (e.g., exercise) emerges as a critical therapeutic goal. Future research must prioritize biomarker validation (claudin-5, S100B), neuroimaging correlations, and targeted BBB-protective therapies to mitigate neurological morbidity in renal disease.
- Open Access
- 4 July 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (27) , e43071
A review of proton beam therapy’s role in glioma management
Gliomas pose significant therapeutic challenges due to limited survival and risks of treatment-related toxicity. Proton beam therapy (PBT) offers a precise radiation delivery method, minimizing damage to healthy brain tissue compared to conventional radiotherapy. This review synthesizes findings from 15 studies (2000–January 2024) from PubMed, Google Scholar, Science Direct, Cochrane Library, and Directory of Open Access Journals. PBT significantly reduces neurocognitive decline and enhances quality of life while achieving comparable or superior survival outcomes across various glioma types, including low-grade gliomas and glioblastomas. Notable benefits include improved verbal memory, stable intellectual functioning, and reduced high-grade toxicity. However, challenges such as neuroendocrine deficiencies and increased radiation necrosis highlight the need for optimized protocols. Future research should focus on comprehensive outcome assessments, proactive management of adverse effects, and improving PBT accessibility through cost reduction and technological advancements. PBT holds transformative potential in glioma management, balancing effective tumor control with preservation of neurological function, positioning it as a valuable neuro-oncology treatment option.
- 4 July 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (27) , e43071
Open AccessA review of proton beam therapy’s role in glioma management
Gliomas pose significant therapeutic challenges due to limited survival and risks of treatment-related toxicity. Proton beam therapy (PBT) offers a precise radiation delivery method, minimizing damage to healthy brain tissue compared to conventional radiotherapy. This review synthesizes findings from 15 studies (2000–January 2024) from PubMed, Google Scholar, Science Direct, Cochrane Library, and Directory of Open Access Journals. PBT significantly reduces neurocognitive decline and enhances quality of life while achieving comparable or superior survival outcomes across various glioma types, including low-grade gliomas and glioblastomas. Notable benefits include improved verbal memory, stable intellectual functioning, and reduced high-grade toxicity. However, challenges such as neuroendocrine deficiencies and increased radiation necrosis highlight the need for optimized protocols. Future research should focus on comprehensive outcome assessments, proactive management of adverse effects, and improving PBT accessibility through cost reduction and technological advancements. PBT holds transformative potential in glioma management, balancing effective tumor control with preservation of neurological function, positioning it as a valuable neuro-oncology treatment option.
- Open Access
- 2 December 2024
- Published by Springer Nature in Discover Medicine
- Vol. 1 (1) , 1-10
Understanding the biological effects of hypoxia in ischemic stroke: implications for rehabilitation and recovery
- 2 December 2024
- Published by Springer Nature in Discover Medicine
- Vol. 1 (1) , 1-10
Open AccessUnderstanding the biological effects of hypoxia in ischemic stroke: implications for rehabilitation and recovery
- Open Access
- 17 July 2024
- Published by Springer Nature in Discover Medicine
- Vol. 1 (1) , 1-11
High-dose vitamin D supplementation in multiple sclerosis: a systematic review of clinical effects and future directions
Vitamin D deficiency is common in multiple sclerosis (MS) patients. This review explores the potential benefits and limitations of high-dose vitamin D supplementation in MS management. We reviewed relevant literature on the effects of high-dose vitamin D supplementation on relapse rates, disability progression, quality of life, and MRI markers of disease activity in MS patients. Additionally, we discussed the mechanisms by which vitamin D might influence MS, potential adverse effects, and future research directions. Studies suggest that high-dose vitamin D supplementation may reduce relapse rates and improve MRI markers of disease activity in MS. However, the evidence for its impact on disability progression and quality of life remains inconclusive. Vitamin D’s immunomodulatory properties are well-documented, and its potential for neuroprotection and neurogenesis warrants further investigation. High-dose vitamin D supplementation holds promise as a complementary or disease-modifying therapy for MS. However, further robust research is required to solidify its role in clinical practice. Exploring vitamin D’s multifaceted effects on the immune system, neuroprotection, and neurogenesis paves the way for novel therapeutic strategies to improve the lives of individuals with MS.
- 17 July 2024
- Published by Springer Nature in Discover Medicine
- Vol. 1 (1) , 1-11
Open AccessHigh-dose vitamin D supplementation in multiple sclerosis: a systematic review of clinical effects and future directions
Vitamin D deficiency is common in multiple sclerosis (MS) patients. This review explores the potential benefits and limitations of high-dose vitamin D supplementation in MS management. We reviewed relevant literature on the effects of high-dose vitamin D supplementation on relapse rates, disability progression, quality of life, and MRI markers of disease activity in MS patients. Additionally, we discussed the mechanisms by which vitamin D might influence MS, potential adverse effects, and future research directions. Studies suggest that high-dose vitamin D supplementation may reduce relapse rates and improve MRI markers of disease activity in MS. However, the evidence for its impact on disability progression and quality of life remains inconclusive. Vitamin D’s immunomodulatory properties are well-documented, and its potential for neuroprotection and neurogenesis warrants further investigation. High-dose vitamin D supplementation holds promise as a complementary or disease-modifying therapy for MS. However, further robust research is required to solidify its role in clinical practice. Exploring vitamin D’s multifaceted effects on the immune system, neuroprotection, and neurogenesis paves the way for novel therapeutic strategies to improve the lives of individuals with MS.
- Open Access
- 28 June 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (26) , e38767
A mini-review of Vutrisiran and Eplontersen in hereditary transthyretin-mediated amyloidosis with polyneuropathy
Hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis), known as Corino de Andrade disease, is a rare neurodegenerative disorder with a significant global impact characterized by the misfolding of transthyretin (TTR) protein leading to amyloid aggregation, ATTRv amyloidosis, especially with polyneuropathy, poses a considerable challenge in managing its rapid progression and debilitating effects. This mini-review focuses on the recent advancements in the treatment landscape for ATTRv amyloidosis with polyneuropathy, specifically the RNA interference therapeutic Vutrisiran and the ligand-conjugated antisense oligonucleotide Eplontersen. We aim to provide a comprehensive overview of the mechanisms, current evidence from clinical trials, and future directions for these novel therapeutic agents. Vutrisiran and Eplontersen have demonstrated significant clinical efficacy in improving neuropathic impairment, quality of life, and serum TTR levels in various trials. The distinct mechanistic approaches of these therapies, coupled with their acceptable safety profiles, offer promising avenues for addressing the complexities of ATTRv amyloidosis with polyneuropathy. The introduction of Vutrisiran and Eplontersen marks a pivotal moment in the quest for effective therapies against ATTRv amyloidosis with polyneuropathy. While clinical evidence is promising, ongoing research is crucial to deepen mechanistic understanding and address research gaps. Future perspectives include the potential expansion of therapeutic options and a more inclusive approach to cater to the diverse needs of individuals globally. This mini-review provides valuable insights into the evolving landscape of ATTRv amyloidosis management and sets the stage for further exploration in this challenging domain.
- 28 June 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (26) , e38767
Open AccessA mini-review of Vutrisiran and Eplontersen in hereditary transthyretin-mediated amyloidosis with polyneuropathy
Hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis), known as Corino de Andrade disease, is a rare neurodegenerative disorder with a significant global impact characterized by the misfolding of transthyretin (TTR) protein leading to amyloid aggregation, ATTRv amyloidosis, especially with polyneuropathy, poses a considerable challenge in managing its rapid progression and debilitating effects. This mini-review focuses on the recent advancements in the treatment landscape for ATTRv amyloidosis with polyneuropathy, specifically the RNA interference therapeutic Vutrisiran and the ligand-conjugated antisense oligonucleotide Eplontersen. We aim to provide a comprehensive overview of the mechanisms, current evidence from clinical trials, and future directions for these novel therapeutic agents. Vutrisiran and Eplontersen have demonstrated significant clinical efficacy in improving neuropathic impairment, quality of life, and serum TTR levels in various trials. The distinct mechanistic approaches of these therapies, coupled with their acceptable safety profiles, offer promising avenues for addressing the complexities of ATTRv amyloidosis with polyneuropathy. The introduction of Vutrisiran and Eplontersen marks a pivotal moment in the quest for effective therapies against ATTRv amyloidosis with polyneuropathy. While clinical evidence is promising, ongoing research is crucial to deepen mechanistic understanding and address research gaps. Future perspectives include the potential expansion of therapeutic options and a more inclusive approach to cater to the diverse needs of individuals globally. This mini-review provides valuable insights into the evolving landscape of ATTRv amyloidosis management and sets the stage for further exploration in this challenging domain.
- Open Access
- 4 April 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (5) , 2408-2410
The potential of smart inhaler for asthma management in Sub-Saharan Africa
An abstract is unavailable. This article is available as a PDF only.
- 4 April 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (5) , 2408-2410
Open AccessThe potential of smart inhaler for asthma management in Sub-Saharan Africa
An abstract is unavailable. This article is available as a PDF only.